ARTICLES BY ANNA ROSE

• 2 Efforts To Keep Payer Policies From Curbing Your Biosimilar’s Uptake

  Many of the articles on this site are focused on how manufacturers can or are working to improve biosimilar uptake. But other stakeholders are aware of the power they, too, hold in improving uptake. One oncologist highlights how she and fellow oncologists are educating stakeholders and drawing greater government attention to payer policy and biosimilar use.

• Biosimilar Competition: Not Your Grandmother’s Generics Market

  To better understand the payer dynamics taking shape in the increasingly competitive oncology space, I spoke with Biosimilar Development editorial advisory board member Kathy Oubre. Here, she highlights the changing dynamics she is observing on the payer front and shares the impact these can have on oncology practices and oncologists’ overall use of biosimilars.

• The Proposed Biosimilar Shared Savings Model: A Closer Look

  Following publication of his recent white paper, I touched base with Alex Brill to better visualize what a shared savings program might look like for biosimilars and to unpack the questions and challenges facing CMMI in establishing such a program.

• Biosimilars In Rheumatology: How To Move The Needle On Uptake, Access

  In this Q&A, one rheumatologist talks through some of the biggest takeaways he had from a recent Cardinal Health survey and how rheumatologists, manufacturers, and payers can better move the biosimilar industry forward for patients.

• Biosimilars, Oral Biologics, & Continuous Processing: One Virtual Biotech’s Strategy

  The (re)emergence of small biotechs in the biosimilar world has caught my eye in the last year. I sat down (virtually) with the CEO of one such company, BiosanaPharma, to discuss the advantages and challenges of being a virtual biotech pursuing biosimilar and novel biologic development.

• 3 P’s In A Pod: Keys For Building A Successful U.S. Biosimilars Market

  In listening to several speakers during a BIO Digital panel, these three talking points added some clarity to the slowly growing discussion on what U.S. biosimilar success will look like.

• Why It’s Time For A U.S. Biosimilar Shared Savings Model

  There's been much discussion about launching a biosimilar shared savings program through the CMMI. In this Q&A, Biosimilars Forum president Julie Reed discusses why this is the best path forward for the U.S. and how The Forum and its members are preparing to ensure its success. 

• How Canada Built A Framework For Biosimilar Transitions In Its Provinces

  Two experts from The pan-Canadian Pharmaceutical Alliance and Cancer Care Ontario discuss the efforts they undertook and challenges they still face in establishing consistent cross-province implementation policies for biosimilars.

• Canada’s Nuanced Healthcare System: Biosimilars In The Private Sector

  The first of this two-part article portrays the complex makeup of the Canadian healthcare system and current stakeholder needs as it relates to biosimilar switching, with a specific focus on the results of one private payer's transition program.

• “Show Me The Data:” New Publication Moves Long-Held Regulatory Debate Forward

  A new peer-reviewed paper, armed with the necessary data, aims to carry us into the days of more tailored biosimilar development. Lead author Martin Schiestl discusses the paper’s most important findings and what implications these data will have for biosimilar developers and regulators.